WallStreetZenWallStreetZen

NASDAQ: OCUL
Ocular Therapeutix Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

OCUL past revenue growth

How has OCUL's revenue growth performed historically?
Company
13.49%
Industry
148.97%
Market
17.57%
OCUL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
OCUL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
OCUL's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

OCUL earnings and revenue history

Current Revenue
$58.4M
Current Earnings
-$80.7M
Current Profit Margin
-138.1%

OCUL Return on Equity

Current Company
-288.9%
Current Industry
-63.5%
Current Market
188%
OCUL's Return on Equity (-288.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when OCUL announces earnings.

OCUL Return on Assets

Current Company
-48.5%
Current Industry
2.9%
OCUL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

OCUL Return on Capital Employed

Current Company
-31.96%
Current Industry
19.5%
OCUL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

OCUL vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
OCUL$58.44M-$66.42M-$80.74M+96.60%N/A
PRTA$91.37M-$152.07M-$147.03M+148.98%N/A
MIRM$186.37M-$135.87M-$163.42M+212.06%N/A
VIR$86.18M-$601.03M-$615.06M+51.87%N/A
MNKD$198.96M$20.62M-$11.94M+48.17%N/A
View Top Biotech Stocks

OCUL earnings dates

Next earnings date
May 6, 2024

Ocular Therapeutix Earnings & Revenue FAQ

What were OCUL's earnings last quarter?

On Invalid Date, Ocular Therapeutix (NASDAQ: OCUL) reported Q4 2023 earnings per share (EPS) of -$0.35, up 75% year over year. Total Ocular Therapeutix earnings for the quarter were -$29.22 million. In the same quarter last year, Ocular Therapeutix's earnings per share (EPS) was -$0.20.

If you're new to stock investing, here's how to buy Ocular Therapeutix stock.

What was OCUL's earnings growth in the past year?

As of Q2 2024, Ocular Therapeutix's earnings has grown year over year. Ocular Therapeutix's earnings in the past year totalled -$80.74 million.

What is OCUL's earnings date?

Ocular Therapeutix's earnings date is Invalid Date. Add OCUL to your watchlist to be reminded of OCUL's next earnings announcement.

What was OCUL's revenue last quarter?

On Invalid Date, Ocular Therapeutix (NASDAQ: OCUL) reported Q4 2023 revenue of $14.80 million up 5.16% year over year. In the same quarter last year, Ocular Therapeutix's revenue was $14.08 million.

What was OCUL's revenue growth in the past year?

As of Q2 2024, Ocular Therapeutix's revenue has grown 13.49% year over year. This is 135.48 percentage points lower than the US Biotechnology industry revenue growth rate of 148.97%. Ocular Therapeutix's revenue in the past year totalled $58.44 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.